You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameChlorthalidone
Accession NumberDB00310  (APRD00127)
TypeSmall Molecule
GroupsApproved
DescriptionA benzenesulfonamide-phthalimidine that tautomerizes to a benzophenones form. It is considered a thiazide-like diuretic. [PubChem]
Structure
Thumb
Synonyms
1-keto-3-(3'-Sulfamyl-4'-chlorophenyl)-3-hydroxyisoindoline
1-oxo-3-(3-Sulfamyl-4-chlorophenyl)-3-hydroxyisoindoline
2-chloro-5-(1-Hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide
2-chloro-5-(2,3-dihydro-1-Hydroxy-3-oxo-1H-isoindol-1-yl)benzenesulfonamide
3-(4'-chloro-3'-Sulfamoylphenyl)-3-hydroxyphthalimidine
3-Hydroxy-3-(4-chloro-3-sulfamylphenyl)phthalimidine
Chlorphthalidolone
Chlortalidone
Chlorthalidone
Phthalamodine
Phthalamudine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ChlorthalidoneTablet50 mgOralAa Pharma Inc1976-12-31Not applicableCanada
Chlorthalidone 100mg TabletsTablet100 mgOralLaboratoires Confab IncNot applicableNot applicableCanada
Chlorthalidone 50mg TabletsTablet50 mgOralLaboratoires Confab IncNot applicableNot applicableCanada
Chlorthalidone Tab 100mgTablet100 mgOralDuchesnay Inc1978-12-312003-07-18Canada
Chlorthalidone Tab 100mgTablet100 mgOralPro Doc Limitee1978-12-311999-08-12Canada
Chlorthalidone Tab 50mgTablet50 mgOralDuchesnay Inc1978-12-312003-07-18Canada
Chlorthalidone Tab 50mgTablet50 mgOralPro Doc Limitee1978-12-311999-08-12Canada
Hygroton 50mgTablet50 mgOralNovartis Pharmaceuticals Canada Inc1968-12-311999-08-04Canada
Novo-thalidone Tab 100mgTablet100 mgOralNovopharm Limited1975-12-312005-08-10Canada
Novo-thalidone Tab 50mgTablet50 mgOralNovopharm Limited1975-12-312005-08-10Canada
ThalitoneTablet15 mg/1OralMonarch Pharmaceuticals, Inc1988-12-20Not applicableUs
Uridon Tab 100mgTablet100 mgOralIcn Canada Ltd.1970-12-312005-04-26Canada
Uridon Tab 50mgTablet50 mgOralIcn Canada Ltd.1974-12-312005-04-26Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Chlorthalidone Tab 100mgTablet100 mgOralApotex Inc1976-12-31Not applicableCanada
ChlorthalidoneTablet25 mg/1OralMylan Institutional Inc.2013-05-03Not applicableUs
ChlorthalidoneTablet25 mg/1OralKAISER FOUNDATION HOSPITALS2009-06-08Not applicableUs
ChlorthalidoneTablet25 mg/1Oralbryant ranch prepack1981-02-26Not applicableUs
ChlorthalidoneTablet25 mg/1OralSun Pharmaceutical Industries, Inc.2016-02-12Not applicableUs
ChlorthalidoneTablet50 mg/1OralAphena Pharma Solutions Tennessee, Llc1981-02-26Not applicableUs
ChlorthalidoneTablet25 mg/1OralPhysicians Total Care, Inc.2003-06-09Not applicableUs
ChlorthalidoneTablet50 mg/1OralMylan Pharmaceuticals Inc.1981-02-26Not applicableUs
ChlorthalidoneTablet25 mg/1OralREMEDYREPACK INC.2008-10-13Not applicableUs
ChlorthalidoneTablet50 mg/1OralSun Pharmaceutical Industries, Inc.2016-02-12Not applicableUs
ChlorthalidoneTablet25 mg/1OralA S Medication Solutions Llc1981-02-26Not applicableUs
ChlorthalidoneTablet25 mg/1OralPd Rx Pharmaceuticals, Inc.2009-11-18Not applicableUs
ChlorthalidoneTablet25 mg/1OralMylan Pharmaceuticals Inc.1981-02-26Not applicableUs
ChlorthalidoneTablet50 mg/1OralLake Erie Medical DBA Quality Care Products LLC1981-02-26Not applicableUs
ChlorthalidoneTablet25 mg/1OralA S Medication Solutions1981-02-26Not applicableUs
ChlorthalidoneTablet50 mg/1OralA S Medication Solutions Llc1981-02-26Not applicableUs
ChlorthalidoneTablet25 mg/1OralRebel Distributors Corp2009-11-18Not applicableUs
ChlorthalidoneTablet50 mg/1OralA S Medication Solutions1981-02-26Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
HygrotonNovartis
SaluretinBalkanpharma
Brand mixtures
NameLabellerIngredients
Apo-atenidoneApotex Inc
Atenolol and ChlorthalidoneMajor Pharmaceutical
ClorpresMylan Pharmaceuticals Inc.
Combipres 0.1/15 TabBoehringer Ingelheim (Canada) Ltd Ltee
EdarbyclorTakeda Pharmaceuticals America, Inc.
Ntp-atenolol/chlorthalidoneTeva Canada Limited
TenoreticAstra Zeneca Pharmaceuticals Lp
Tenoretic 100/25mg TabAstrazeneca Canada Inc
Tenoretic 50/25mg TabAstrazeneca Canada Inc
Teva-atenolol/chlorthalidoneTeva Canada Limited
SaltsNot Available
Categories
UNIIQ0MQD1073Q
CAS number77-36-1
WeightAverage: 338.766
Monoisotopic: 338.012805247
Chemical FormulaC14H11ClN2O4S
InChI KeyJIVPVXMEBJLZRO-UHFFFAOYSA-N
InChI
InChI=1S/C14H11ClN2O4S/c15-11-6-5-8(7-12(11)22(16,20)21)14(19)10-4-2-1-3-9(10)13(18)17-14/h1-7,19H,(H,17,18)(H2,16,20,21)
IUPAC Name
2-chloro-5-(1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)benzene-1-sulfonamide
SMILES
NS(=O)(=O)C1=C(Cl)C=CC(=C1)C1(O)NC(=O)C2=CC=CC=C12
Pharmacology
IndicationFor management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension.
Structured Indications
PharmacodynamicsChlorthalidone, a monosulfonamyl diuretic, differs form other thiazide diuretics in that a double ring system is incorporated into its structure. Chlorthalidone is used alone or with atenolol in the management of hypertension and edema.
Mechanism of actionChlorthalidone inhibits sodium ion transport across the renal tubular epithelium in the cortical diluting segment of the ascending limb of the loop of Henle. By increasing the delivery of sodium to the distal renal tubule, Chlorthalidone indirectly increases potassium excretion via the sodium-potassium exchange mechanism.
TargetKindPharmacological actionActionsOrganismUniProt ID
Solute carrier family 12 member 1Proteinyes
inhibitor
HumanQ13621 details
Related Articles
AbsorptionAbsorbed relatively rapidly after oral administration.
Volume of distributionNot Available
Protein bindingHigh (75% [58% to albumin])
Metabolism

Liver

Route of eliminationThe major portion of the drug is excreted unchanged by the kidneys.
Half life40 hours
ClearanceNot Available
ToxicitySymptoms of overdose include nausea, weakness, dizziness and disturbances of electrolyte balance.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Chlorthalidone Action PathwayDrug actionSMP00122
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Chlorthalidone.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Chlorthalidone.Experimental, Illicit
4-Androstenedione4-Androstenedione may increase the hypokalemic activities of Chlorthalidone.Experimental, Illicit
5-androstenedione5-androstenedione may increase the hypokalemic activities of Chlorthalidone.Experimental, Illicit
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Chlorthalidone.Experimental
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Chlorthalidone.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Acebutolol.Approved
AceclofenacThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Aceclofenac.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Acetazolamide.Approved, Vet Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Chlorthalidone.Withdrawn
AcetovanilloneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Acetovanillone.Investigational
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Acetyldigitoxin.Approved
Acetylsalicylic acidThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AclidiniumThe serum concentration of Chlorthalidone can be increased when it is combined with Aclidinium.Approved
AdapaleneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Adapalene.Approved
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Chlorthalidone.Experimental
AlclometasoneAlclometasone may increase the hypokalemic activities of Chlorthalidone.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Chlorthalidone.Approved
AldosteroneAldosterone may increase the hypokalemic activities of Chlorthalidone.Experimental
AlfacalcidolChlorthalidone may increase the hypercalcemic activities of Alfacalcidol.Approved, Nutraceutical
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Chlorthalidone.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Chlorthalidone.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Aliskiren.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Chlorthalidone.Approved
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Chlorthalidone.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Chlorthalidone.Experimental, Illicit
AlprenololChlorthalidone may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanChlorthalidone may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmcinonideAmcinonide may increase the hypokalemic activities of Chlorthalidone.Approved
AmifostineChlorthalidone may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Amiloride.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the orthostatic hypotensive activities of Chlorthalidone.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Amyl Nitrite.Approved
AnecortaveAnecortave may increase the hypokalemic activities of Chlorthalidone.Investigational
AnisodamineThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Anisodamine.Investigational
Anisotropine MethylbromideThe serum concentration of Chlorthalidone can be increased when it is combined with Anisotropine Methylbromide.Approved
AntipyrineThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Antipyrine.Approved
AnvirzelThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Anvirzel.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Apraclonidine.Approved
ApremilastThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Apremilast.Approved, Investigational
ArbutamineArbutamine may increase the hypokalemic activities of Chlorthalidone.Approved
ArformoterolArformoterol may increase the hypokalemic activities of Chlorthalidone.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Chlorthalidone.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Arsenic trioxide.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Atenolol.Approved
Atracurium besylateThe serum concentration of Chlorthalidone can be increased when it is combined with Atracurium besylate.Approved
AtropineThe serum concentration of Chlorthalidone can be increased when it is combined with Atropine.Approved, Vet Approved
AzapropazoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Azilsartan medoxomil.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Chlorthalidone.Investigational
BalsalazideThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Balsalazide.Approved, Investigational
BambuterolBambuterol may increase the hypokalemic activities of Chlorthalidone.Approved
BarbexacloneBarbexaclone may increase the orthostatic hypotensive activities of Chlorthalidone.Experimental
BarbitalBarbital may increase the orthostatic hypotensive activities of Chlorthalidone.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Barnidipine.Approved
BeclomethasoneBeclomethasone may increase the hypokalemic activities of Chlorthalidone.Investigational
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Chlorthalidone.Approved, Investigational
BenactyzineThe serum concentration of Chlorthalidone can be increased when it is combined with Benactyzine.Withdrawn
BenazeprilThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Chlorthalidone.Withdrawn
BenoxaprofenThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzatropineThe serum concentration of Chlorthalidone can be increased when it is combined with Benzatropine.Approved
BepridilChlorthalidone may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetamethasoneBetamethasone may increase the hypokalemic activities of Chlorthalidone.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Chlorthalidone.Approved
BethanidineBethanidine may increase the hypotensive activities of Chlorthalidone.Approved
Betulinic AcidThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Betulinic Acid.Investigational
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Chlorthalidone.Experimental, Illicit, Withdrawn
BimatoprostChlorthalidone may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BiperidenThe serum concentration of Chlorthalidone can be increased when it is combined with Biperiden.Approved
BisoprololThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Bisoprolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Bortezomib.Approved, Investigational
BosentanChlorthalidone may increase the hypotensive activities of Bosentan.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Chlorthalidone.Approved
BromfenacThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Bromocriptine.Approved, Investigational
BucillamineThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Bucillamine.Investigational
BudesonideBudesonide may increase the hypokalemic activities of Chlorthalidone.Approved
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Chlorthalidone.Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Bupivacaine.Approved, Investigational
BupranololChlorthalidone may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Chlorthalidone.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Chlorthalidone.Approved, Illicit, Vet Approved
CalcidiolChlorthalidone may increase the hypercalcemic activities of Calcidiol.Approved, Nutraceutical
CalcipotriolChlorthalidone may increase the hypercalcemic activities of Calcipotriol.Approved
CalcitriolChlorthalidone may increase the hypercalcemic activities of Calcitriol.Approved, Nutraceutical
CalciumChlorthalidone may decrease the excretion rate of Calcium which could result in a higher serum level.Nutraceutical
Calcium AcetateChlorthalidone may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved
Calcium carbonateChlorthalidone may decrease the excretion rate of Calcium carbonate which could result in a higher serum level.Approved
Calcium ChlorideChlorthalidone may decrease the excretion rate of Calcium Chloride which could result in a higher serum level.Approved
Calcium citrateChlorthalidone may decrease the excretion rate of Calcium citrate which could result in a higher serum level.Approved
Calcium glubionateChlorthalidone may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.Approved
Calcium GluceptateChlorthalidone may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.Approved
Calcium gluconateChlorthalidone may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.Approved, Vet Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Candesartan.Approved
CandoxatrilChlorthalidone may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Carbetocin.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Chlorthalidone.Illicit, Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Chlorthalidone.Withdrawn
CarprofenThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Carteolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Carvedilol.Approved, Investigational
CastanospermineThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypokalemic activities of Chlorthalidone.Approved, Investigational
ChloroquineThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenoxamineThe serum concentration of Chlorthalidone can be increased when it is combined with Chlorphenoxamine.Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Chlorthalidone.Approved
CholecalciferolChlorthalidone may increase the hypercalcemic activities of Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Chlorthalidone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Chlorthalidone.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Chlorthalidone.Experimental
CilazaprilThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Cilnidipine.Approved
CitalopramCitalopram may increase the hyponatremic activities of Chlorthalidone.Approved
ClenbuterolClenbuterol may increase the hypokalemic activities of Chlorthalidone.Approved, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Clevidipine.Approved
ClobetasolClobetasol may increase the hypokalemic activities of Chlorthalidone.Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Chlorthalidone.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Chlorthalidone.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Clonidine.Approved
ClonixinThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Clonixin.Approved
ClozapineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Clozapine.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Chlorthalidone.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Chlorthalidone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Chlorthalidone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Conivaptan.Approved, Investigational
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Chlorthalidone.Approved
CryptenamineChlorthalidone may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Curcumin.Investigational
CyclopentolateThe serum concentration of Chlorthalidone can be increased when it is combined with Cyclopentolate.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Cyclophosphamide.Approved, Investigational
CyclothiazideChlorthalidone may increase the hypotensive activities of Cyclothiazide.Approved
D-LimoneneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with D-Limonene.Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the hyponatremic activities of Chlorthalidone.Investigational
DarifenacinThe serum concentration of Chlorthalidone can be increased when it is combined with Darifenacin.Approved, Investigational
DebrisoquinChlorthalidone may increase the hypotensive activities of Debrisoquin.Approved
dehydroepiandrosterone sulfatedehydroepiandrosterone sulfate may increase the hypokalemic activities of Chlorthalidone.Investigational
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Chlorthalidone.Investigational
DeserpidineChlorthalidone may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Desflurane.Approved
DeslanosideThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Deslanoside.Approved
DesloratadineThe serum concentration of Chlorthalidone can be increased when it is combined with Desloratadine.Approved, Investigational
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Chlorthalidone.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Chlorthalidone.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Chlorthalidone.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the hyponatremic activities of Chlorthalidone.Approved
DexamethasoneDexamethasone may increase the hypokalemic activities of Chlorthalidone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Chlorthalidone.Vet Approved
DexetimideThe serum concentration of Chlorthalidone can be increased when it is combined with Dexetimide.Withdrawn
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Chlorthalidone.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Chlorthalidone.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chlorthalidone.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Chlorthalidone.Approved
DiazoxideThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Diazoxide.Approved
DiclofenacThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Diclofenamide.Approved
DicyclomineThe serum concentration of Chlorthalidone can be increased when it is combined with Dicyclomine.Approved
DiflorasoneDiflorasone may increase the hypokalemic activities of Chlorthalidone.Approved
DiflunisalThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Diflunisal.Approved
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Chlorthalidone.Approved
DifluprednateDifluprednate may increase the hypokalemic activities of Chlorthalidone.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Digitoxin.Approved
DigoxinThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Digoxin.Approved
DihydralazineChlorthalidone may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chlorthalidone.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Chlorthalidone.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Chlorthalidone.Experimental, Illicit
DihydrotachysterolChlorthalidone may increase the hypercalcemic activities of Dihydrotachysterol.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Dinutuximab.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chlorthalidone.Approved, Illicit
DipivefrinDipivefrin may increase the hypokalemic activities of Chlorthalidone.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Dipyridamole.Approved
DobutamineDobutamine may increase the hypokalemic activities of Chlorthalidone.Approved
DofetilideChlorthalidone may increase the QTc-prolonging activities of Dofetilide.Approved
DorzolamideChlorthalidone may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Doxazosin.Approved
DoxercalciferolChlorthalidone may increase the hypercalcemic activities of Doxercalciferol.Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Chlorthalidone.Investigational
DroxicamThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Droxicam.Approved
DroxidopaDroxidopa may increase the hypokalemic activities of Chlorthalidone.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Chlorthalidone.Approved
DuloxetineChlorthalidone may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Duvelisib.Investigational
E6201The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with E6201.Investigational
EbselenThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Ebselen.Investigational
EfonidipineChlorthalidone may increase the hypotensive activities of Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Enalapril.Approved, Vet Approved
EnalaprilatChlorthalidone may increase the hypotensive activities of Enalaprilat.Approved
EphedraEphedra may increase the hypokalemic activities of Chlorthalidone.Approved, Nutraceutical, Withdrawn
EpinephrineEpinephrine may increase the hypokalemic activities of Chlorthalidone.Approved, Vet Approved
EpirizoleThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Epirizole.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Eplerenone.Approved
EpoprostenolChlorthalidone may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Eprosartan.Approved
EquileninEquilenin may increase the hypokalemic activities of Chlorthalidone.Experimental
EquilinEquilin may increase the hypokalemic activities of Chlorthalidone.Approved
ErgocalciferolChlorthalidone may increase the hypercalcemic activities of Ergocalciferol.Approved, Nutraceutical
EscitalopramEscitalopram may increase the hyponatremic activities of Chlorthalidone.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Chlorthalidone.Approved
EstroneEstrone may increase the hypokalemic activities of Chlorthalidone.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Chlorthalidone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Etacrynic acid.Approved
EtanerceptThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Etanercept.Approved, Investigational
EthanolEthanol may increase the orthostatic hypotensive activities of Chlorthalidone.Approved
EthopropazineThe serum concentration of Chlorthalidone can be increased when it is combined with Ethopropazine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Chlorthalidone.Approved, Illicit
EtodolacThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Etofenamate.Approved
EtoperidoneEtoperidone may increase the hyponatremic activities of Chlorthalidone.Approved
EtoricoxibThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Chlorthalidone.Illicit, Vet Approved
Evening primrose oilThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Evening primrose oil.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Chlorthalidone.Approved, Investigational
exisulindThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with exisulind.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Felodipine.Approved, Investigational
FenbufenThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Fenbufen.Approved
FenoldopamChlorthalidone may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Fenoprofen.Approved
FenoterolFenoterol may increase the hypokalemic activities of Chlorthalidone.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chlorthalidone.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Chlorthalidone can be increased when it is combined with Fesoterodine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Fimasartan.Approved
FloctafenineThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Floctafenine.Approved, Withdrawn
fluasteronefluasterone may increase the hypokalemic activities of Chlorthalidone.Investigational
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Chlorthalidone.Approved
FlumethasoneFlumethasone may increase the hypokalemic activities of Chlorthalidone.Approved, Vet Approved
FlunisolideFlunisolide may increase the hypokalemic activities of Chlorthalidone.Approved, Investigational
FlunixinThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Flunixin.Vet Approved
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Chlorthalidone.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Chlorthalidone.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Chlorthalidone.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Chlorthalidone.Approved
FluoxetineFluoxetine may increase the hyponatremic activities of Chlorthalidone.Approved, Vet Approved
FluprednideneFluprednidene may increase the hypokalemic activities of Chlorthalidone.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Chlorthalidone.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Chlorthalidone.Approved
FlurbiprofenThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Flurbiprofen.Approved, Investigational
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Chlorthalidone.Approved
Fluticasone PropionateFluticasone Propionate may increase the hypokalemic activities of Chlorthalidone.Approved
FluvoxamineFluvoxamine may increase the hyponatremic activities of Chlorthalidone.Approved, Investigational
FormestaneFormestane may increase the hypokalemic activities of Chlorthalidone.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the hypokalemic activities of Chlorthalidone.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Fosinopril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Chlorthalidone.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Furosemide.Approved, Vet Approved
Gallamine TriethiodideThe serum concentration of Chlorthalidone can be increased when it is combined with Gallamine Triethiodide.Approved
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Chlorthalidone.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Chlorthalidone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Chlorthalidone.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Chlorthalidone.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Chlorthalidone.Approved
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Chlorthalidone.Approved
GlycopyrroniumThe serum concentration of Chlorthalidone can be increased when it is combined with Glycopyrronium.Approved, Investigational, Vet Approved
GuanabenzChlorthalidone may increase the hypotensive activities of Guanabenz.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Chlorthalidone.Approved
GuanethidineChlorthalidone may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Guanfacine.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Chlorthalidone.Investigational
HalothaneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Halothane.Approved, Vet Approved
HE3286HE3286 may increase the hypokalemic activities of Chlorthalidone.Investigational
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Chlorthalidone.Approved, Illicit
HexamethoniumThe serum concentration of Chlorthalidone can be increased when it is combined with Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the orthostatic hypotensive activities of Chlorthalidone.Approved
HigenamineThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Higenamine.Investigational
HMPL-004The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with HMPL-004.Investigational
HomatropineThe serum concentration of Chlorthalidone can be increased when it is combined with Homatropine.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Chlorthalidone.Approved
HydralazineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Chlorthalidone.Approved, Illicit
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Chlorthalidone.Approved, Vet Approved
HydroflumethiazideChlorthalidone may increase the hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorthalidone.Approved, Illicit
HyoscyamineThe serum concentration of Chlorthalidone can be increased when it is combined with Hyoscyamine.Approved
IbuprofenThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Icatibant.Approved
IloprostIloprost may increase the hypotensive activities of Chlorthalidone.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Imipramine.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Chlorthalidone.Approved
IndalpineIndalpine may increase the hyponatremic activities of Chlorthalidone.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Indapamide.Approved
IndenololChlorthalidone may increase the hypotensive activities of Indenolol.Withdrawn
IndomethacinThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminChlorthalidone may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Chlorthalidone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Chlorthalidone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Chlorthalidone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Chlorthalidone.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Chlorthalidone.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Chlorthalidone.Approved
Ipratropium bromideThe serum concentration of Chlorthalidone can be increased when it is combined with Ipratropium bromide.Approved
IproclozideIproclozide may increase the hypotensive activities of Chlorthalidone.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Chlorthalidone.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Chlorthalidone.Approved
IsoetarineIsoetarine may increase the hypokalemic activities of Chlorthalidone.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Isoflurane.Approved, Vet Approved
IsoprenalineIsoprenaline may increase the hypokalemic activities of Chlorthalidone.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Isosorbide Mononitrate.Approved
IsoxicamThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Chlorthalidone.Approved
IstaroximeIstaroxime may increase the hypokalemic activities of Chlorthalidone.Investigational
IvabradineChlorthalidone may increase the arrhythmogenic activities of Ivabradine.Approved
KebuzoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Kebuzone.Experimental
KetanserinChlorthalidone may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Chlorthalidone.Approved
KetoprofenThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Labetalol.Approved
LacidipineChlorthalidone may increase the hypotensive activities of Lacidipine.Approved
LatanoprostChlorthalidone may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Leflunomide.Approved, Investigational
LercanidipineChlorthalidone may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Levobupivacaine.Approved
LevodopaChlorthalidone may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Chlorthalidone.Approved
LevomilnacipranLevomilnacipran may increase the hyponatremic activities of Chlorthalidone.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Chlorthalidone.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Levosimendan.Approved, Investigational
LicoriceLicorice may increase the hypokalemic activities of Chlorthalidone.Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Chlorthalidone.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Chlorthalidone.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Lisinopril.Approved, Investigational
LisofyllineThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Lisofylline.Investigational
LithiumChlorthalidone may decrease the excretion rate of Lithium which could result in a higher serum level.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Chlorthalidone.Illicit
LofexidineChlorthalidone may increase the hypotensive activities of Lofexidine.Approved, Investigational
LornoxicamThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Losartan.Approved
LoxoprofenThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Loxoprofen.Approved
LumiracoxibThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Lumiracoxib.Approved, Investigational
MacitentanChlorthalidone may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Magnesium salicylate.Approved
ManidipineChlorthalidone may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Mannitol.Approved, Investigational
MasoprocolThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Masoprocol.Approved
ME-609ME-609 may increase the hypokalemic activities of Chlorthalidone.Investigational
MebanazineMebanazine may increase the hypotensive activities of Chlorthalidone.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Mecamylamine.Approved
Meclofenamic acidThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
MedrysoneMedrysone may increase the hypokalemic activities of Chlorthalidone.Approved
Mefenamic acidThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Mefenamic acid.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Chlorthalidone.Vet Approved
MeloxicamThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MesalazineThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Metamizole.Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Chlorthalidone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Chlorthalidone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Chlorthalidone.Approved, Illicit
MethanthelineThe serum concentration of Chlorthalidone can be increased when it is combined with Methantheline.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the orthostatic hypotensive activities of Chlorthalidone.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Chlorthalidone.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Chlorthalidone.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Chlorthalidone.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the orthostatic hypotensive activities of Chlorthalidone.Approved
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Chlorthalidone.Approved, Vet Approved
MetipranololThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Metipranolol.Approved
MetixeneThe serum concentration of Chlorthalidone can be increased when it is combined with Metixene.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Chlorthalidone.Approved, Investigational
MetyrosineChlorthalidone may increase the hypotensive activities of Metyrosine.Approved
MibefradilChlorthalidone may increase the hypotensive activities of Mibefradil.Withdrawn
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Chlorthalidone.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Chlorthalidone.Approved
MilnacipranMilnacipran may increase the hyponatremic activities of Chlorthalidone.Approved
MinaprineMinaprine may increase the hypotensive activities of Chlorthalidone.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Minoxidil.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Chlorthalidone.Approved, Investigational
MizoribineThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Chlorthalidone.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Chlorthalidone.Approved
MometasoneMometasone may increase the hypokalemic activities of Chlorthalidone.Approved, Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Chlorthalidone.Approved, Investigational
MoxonidineChlorthalidone may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Mycophenolic acid.Approved
N-butylscopolammonium bromideThe serum concentration of Chlorthalidone can be increased when it is combined with N-butylscopolammonium bromide.Vet Approved
NabiloneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Nabilone.Approved, Investigational
NabumetoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Nadolol.Approved
NafamostatThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Nafamostat.Investigational
NaftifineThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Naftifine.Approved
NaftopidilChlorthalidone may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Chlorthalidone.Approved
NaproxenThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Naproxen.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Chlorthalidone.Approved, Investigational
NCX 1022NCX 1022 may increase the hypokalemic activities of Chlorthalidone.Investigational
NCX 4016The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with NCX 4016.Investigational
NebivololThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the hyponatremic activities of Chlorthalidone.Approved, Withdrawn
NepafenacThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Chlorthalidone.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Chlorthalidone.Approved
NifedipineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Nifedipine.Approved
Niflumic AcidThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Niflumic Acid.Approved
NiguldipineChlorthalidone may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineChlorthalidone may increase the hypotensive activities of Nilvadipine.Approved
NimesulideThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Nisoldipine.Approved
NitrendipineChlorthalidone may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Nitric Oxide.Approved
NitroaspirinThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Nitroprusside.Approved
NorepinephrineNorepinephrine may increase the hypokalemic activities of Chlorthalidone.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Chlorthalidone.Approved, Illicit
NVA237The serum concentration of Chlorthalidone can be increased when it is combined with NVA237.Investigational
ObinutuzumabChlorthalidone may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Chlorthalidone.Withdrawn
Oleoyl estroneOleoyl estrone may increase the hypokalemic activities of Chlorthalidone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Chlorthalidone.Approved, Investigational
OlodaterolOlodaterol may increase the hypokalemic activities of Chlorthalidone.Approved
OlopatadineThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Olsalazine.Approved
OmapatrilatChlorthalidone may increase the hypotensive activities of Omapatrilat.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Chlorthalidone.Approved, Illicit
OrciprenalineOrciprenaline may increase the hypokalemic activities of Chlorthalidone.Approved
OrgoteinThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Orgotein.Vet Approved
OrphenadrineThe serum concentration of Chlorthalidone can be increased when it is combined with Orphenadrine.Approved
OuabainThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Ouabain.Approved
OxaprozinThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Oxaprozin.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Oxcarbazepine.Approved
OxprenololChlorthalidone may increase the hypotensive activities of Oxprenolol.Approved
OxybutyninThe serum concentration of Chlorthalidone can be increased when it is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chlorthalidone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Chlorthalidone.Approved, Investigational, Vet Approved
OxyphenbutazoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Oxyphenbutazone.Withdrawn
OxyphenoniumThe serum concentration of Chlorthalidone can be increased when it is combined with Oxyphenonium.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Paclitaxel.Approved, Vet Approved
PancuroniumThe serum concentration of Chlorthalidone can be increased when it is combined with Pancuronium.Approved
PapaverineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Papaverine.Approved
ParamethasoneParamethasone may increase the hypokalemic activities of Chlorthalidone.Approved
ParecoxibThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Chlorthalidone.Approved
ParicalcitolChlorthalidone may increase the hypercalcemic activities of Paricalcitol.Approved, Investigational
ParoxetineParoxetine may increase the hyponatremic activities of Chlorthalidone.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorthalidone.Approved, Vet Approved
PentobarbitalPentobarbital may increase the orthostatic hypotensive activities of Chlorthalidone.Approved, Vet Approved
PentoliniumThe serum concentration of Chlorthalidone can be increased when it is combined with Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Chlorthalidone.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Chlorthalidone.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Chlorthalidone.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Chlorthalidone.Approved, Withdrawn
PheniprazinePheniprazine may increase the hypotensive activities of Chlorthalidone.Withdrawn
PhenobarbitalPhenobarbital may increase the orthostatic hypotensive activities of Chlorthalidone.Approved
PhenoxybenzamineChlorthalidone may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Chlorthalidone.Withdrawn
PhentolamineChlorthalidone may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Chlorthalidone.Approved, Vet Approved, Withdrawn
PimecrolimusThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PinacidilChlorthalidone may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Pindolol.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Chlorthalidone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Pipamperone.Approved
PipecuroniumThe serum concentration of Chlorthalidone can be increased when it is combined with Pipecuronium.Approved
PirbuterolPirbuterol may increase the hypokalemic activities of Chlorthalidone.Approved
PirenzepineThe serum concentration of Chlorthalidone can be increased when it is combined with Pirenzepine.Approved
PirfenidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Pirfenidone.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Chlorthalidone.Investigational
PirlindolePirlindole may increase the hypotensive activities of Chlorthalidone.Approved
PiroxicamThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Piroxicam.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Chlorthalidone.Withdrawn
PolythiazideChlorthalidone may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Chlorthalidone.Approved, Investigational
PrasteronePrasterone may increase the hypokalemic activities of Chlorthalidone.Approved, Nutraceutical
PrazosinThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Prazosin.Approved
PrednicarbatePrednicarbate may increase the hypokalemic activities of Chlorthalidone.Approved
PrednisolonePrednisolone may increase the hypokalemic activities of Chlorthalidone.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Chlorthalidone.Approved, Vet Approved
PregnenolonePregnenolone may increase the hypokalemic activities of Chlorthalidone.Experimental
PrimidonePrimidone may increase the orthostatic hypotensive activities of Chlorthalidone.Approved, Vet Approved
ProcaterolProcaterol may increase the hypokalemic activities of Chlorthalidone.Approved
ProcyclidineThe serum concentration of Chlorthalidone can be increased when it is combined with Procyclidine.Approved
PropacetamolThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Propacetamol.Approved
PropanthelineThe serum concentration of Chlorthalidone can be increased when it is combined with Propantheline.Approved
PropiverineThe serum concentration of Chlorthalidone can be increased when it is combined with Propiverine.Investigational
PropofolThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Propranolol.Approved, Investigational
PTC299The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Chlorthalidone can be increased when it is combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Chlorthalidone.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Chlorthalidone.Approved
RasagilineRasagiline may increase the hypotensive activities of Chlorthalidone.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chlorthalidone.Approved
RemikirenRemikiren may increase the hypotensive activities of Chlorthalidone.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Chlorthalidone.Approved, Investigational
RescinnamineChlorthalidone may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Chlorthalidone.Approved
ResveratrolThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Resveratrol.Experimental, Investigational
RilmenidineChlorthalidone may increase the hypotensive activities of Rilmenidine.Investigational
RimexoloneRimexolone may increase the hypokalemic activities of Chlorthalidone.Approved
RiociguatThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Riociguat.Approved
RisperidoneChlorthalidone may increase the hypotensive activities of Risperidone.Approved, Investigational
RitodrineRitodrine may increase the hypokalemic activities of Chlorthalidone.Approved
RituximabChlorthalidone may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Ropivacaine.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Chlorthalidone.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Chlorthalidone.Withdrawn
SalbutamolSalbutamol may increase the hypokalemic activities of Chlorthalidone.Approved, Vet Approved
SalicylamideThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
SalmeterolSalmeterol may increase the hypokalemic activities of Chlorthalidone.Approved
SalsalateThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Salsalate.Approved
SaprisartanChlorthalidone may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Chlorthalidone.Approved
ScopolamineThe serum concentration of Chlorthalidone can be increased when it is combined with Scopolamine.Approved
Scopolamine butylbromideThe serum concentration of Chlorthalidone can be increased when it is combined with Scopolamine butylbromide.Approved
SecobarbitalSecobarbital may increase the orthostatic hypotensive activities of Chlorthalidone.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Chlorthalidone.Approved, Investigational, Vet Approved
SelexipagChlorthalidone may increase the hypotensive activities of Selexipag.Approved
SeratrodastThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Seratrodast.Approved, Investigational
SertralineSertraline may increase the hyponatremic activities of Chlorthalidone.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Chlorthalidone.Approved, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Chlorthalidone.Approved, Investigational
SitaxentanChlorthalidone may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Sodium Nitrite.Approved
SolifenacinThe serum concentration of Chlorthalidone can be increased when it is combined with Solifenacin.Approved
SotalolThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Sotalol.Approved
SpiraprilChlorthalidone may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Spironolactone.Approved
SRT501The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with SRT501.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorthalidone.Approved, Investigational
SulfasalazineThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Sulindac.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Chlorthalidone.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Sulpiride.Approved
SuprofenThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Suprofen.Approved, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Chlorthalidone.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Tamsulosin.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Chlorthalidone.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Telmisartan.Approved, Investigational
TemocaprilChlorthalidone may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenoxicamThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Terazosin.Approved
TerbutalineTerbutaline may increase the hypokalemic activities of Chlorthalidone.Approved
TeriflunomideThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Teriflunomide.Approved
TerlipressinChlorthalidone may increase the hypotensive activities of Terlipressin.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the orthostatic hypotensive activities of Chlorthalidone.Approved, Vet Approved
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Chlorthalidone.Investigational
ThiopentalThiopental may increase the orthostatic hypotensive activities of Chlorthalidone.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Thioridazine.Approved
Tiaprofenic acidThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Tiaprofenic acid.Approved
TiboloneChlorthalidone may increase the hypotensive activities of Tibolone.Approved
TicrynafenChlorthalidone may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Timolol.Approved
TinoridineThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Tinoridine.Investigational
TiotropiumThe serum concentration of Chlorthalidone can be increased when it is combined with Tiotropium.Approved
TixocortolTixocortol may increase the hypokalemic activities of Chlorthalidone.Approved
TizanidineThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Tizanidine.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Chlorthalidone.Approved
TolazolineChlorthalidone may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Chlorthalidone.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Tolfenamic Acid.Approved
TolmetinThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Tolmetin.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Chlorthalidone.Approved
TolterodineThe serum concentration of Chlorthalidone can be increased when it is combined with Tolterodine.Approved, Investigational
TopiramateChlorthalidone may increase the hypokalemic activities of Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Chlorthalidone.Approved
ToremifeneChlorthalidone may increase the hypercalcemic activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Chlorthalidone.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Trandolapril.Approved
TranilastThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Chlorthalidone.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Chlorthalidone.Approved
TravoprostTravoprost may increase the hypotensive activities of Chlorthalidone.Approved
TreprostinilChlorthalidone may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Chlorthalidone.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Triamterene.Approved
TrichlormethiazideChlorthalidone may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrihexyphenidylThe serum concentration of Chlorthalidone can be increased when it is combined with Trihexyphenidyl.Approved
TrimazosinChlorthalidone may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanThe serum concentration of Chlorthalidone can be increased when it is combined with Trimethaphan.Approved
Trisalicylate-cholineThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Trisalicylate-choline.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Chlorthalidone.Withdrawn
TropicamideThe serum concentration of Chlorthalidone can be increased when it is combined with Tropicamide.Approved
TrospiumThe serum concentration of Chlorthalidone can be increased when it is combined with Trospium.Approved
TubocurarineThe serum concentration of Chlorthalidone can be increased when it is combined with Tubocurarine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Chlorthalidone.Approved, Investigational
UmeclidiniumThe serum concentration of Chlorthalidone can be increased when it is combined with Umeclidinium.Approved
UnoprostoneChlorthalidone may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Valdecoxib.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Chlorthalidone.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Chlorthalidone.Approved
VecuroniumThe serum concentration of Chlorthalidone can be increased when it is combined with Vecuronium.Approved
VenlafaxineVenlafaxine may increase the hyponatremic activities of Chlorthalidone.Approved
VerapamilThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Verapamil.Approved
VilanterolVilanterol may increase the hypokalemic activities of Chlorthalidone.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Chlorthalidone.Approved, Investigational
VinpocetineChlorthalidone may increase the hypotensive activities of Vinpocetine.Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Chlorthalidone.Approved, Investigational
XylometazolineChlorthalidone may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Chlorthalidone.Approved, Vet Approved
ZaltoprofenThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Zaltoprofen.Approved
ZileutonThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the hyponatremic activities of Chlorthalidone.Withdrawn
ZomepiracThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Zomepirac.Withdrawn
Food Interactions
  • Take with food (increases availability).
References
Synthesis Reference

Graf, W., Schmid, E. and Stoll, W.G.; US Patent 3,055,904; September 25,1962; assigned
to Geigy Chemical Corporation.

General ReferencesNot Available
External Links
ATC CodesC03BA04C03BB04C03EA06
AHFS Codes
  • 40:28.24
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.5447
Caco-2 permeable-0.6272
P-glycoprotein substrateNon-substrate0.767
P-glycoprotein inhibitor INon-inhibitor0.9603
P-glycoprotein inhibitor IINon-inhibitor0.9573
Renal organic cation transporterNon-inhibitor0.891
CYP450 2C9 substrateNon-substrate0.6403
CYP450 2D6 substrateNon-substrate0.822
CYP450 3A4 substrateNon-substrate0.6369
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9299
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8193
Ames testNon AMES toxic0.7277
CarcinogenicityNon-carcinogens0.5752
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.8623 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9968
hERG inhibition (predictor II)Non-inhibitor0.8914
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Abbott laboratories pharmaceutical products div
  • Ascot hosp pharmaceuticals inc div travenol laboratories inc
  • Clonmel healthcare ltd
  • Ivax pharmaceuticals inc
  • Kv pharmaceutical co
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Pioneer pharmaceuticals inc
  • Pliva inc
  • Purepac pharmaceutical co
  • Sandoz inc
  • Superpharm corp
  • Teva pharmaceuticals usa inc
  • Usl pharma inc
  • Vangard laboratories inc div midway medical co
  • Warner chilcott div warner lambert co
  • Watson laboratories inc
  • Sanofi aventis us llc
  • Monarch pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
TabletOral100 mg
TabletOral25 mg/1
TabletOral50 mg/1
TabletOral50 mg
TabletOral
TabletOral15 mg/1
Prices
Unit descriptionCostUnit
Tenoretic 100 100-25 mg tablet2.91USD tablet
Tenoretic 100 tablet2.91USD tablet
Tenoretic 50 50-25 mg tablet2.18USD tablet
Tenoretic 50 tablet2.07USD tablet
Thalitone 15 mg tablet1.55USD tablet
Chlorthalidone 100 mg tablet1.07USD tablet
Chlorthalidone 50 mg tablet0.46USD tablet
Chlorthalidone 25 mg tablet0.28USD tablet
Apo-Chlorthalidone 50 mg Tablet0.13USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7157584 No2005-05-222025-05-22Us
US7572920 No2005-01-072025-01-07Us
US9066936 No2008-03-262028-03-26Us
US9169238 No2010-02-252030-02-25Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point239 °CPhysProp
water solubility120 mg/L (at 20 °C)MERCK INDEX (1996)
logP0.85BERTHOD,A ET AL. (1999)
Predicted Properties
PropertyValueSource
Water Solubility0.0528 mg/mLALOGPS
logP1.27ALOGPS
logP1.6ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)8.58ChemAxon
pKa (Strongest Basic)-2.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area109.49 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity81.3 m3·mol-1ChemAxon
Polarizability31.23 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as isoindolones. These are aromatic polycyclic compounds that an isoindole bearing a ketone.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIsoindoles and derivatives
Sub ClassIsoindolines
Direct ParentIsoindolones
Alternative Parents
Substituents
  • Isoindolone
  • Benzenesulfonamide
  • Isoindole
  • Halobenzene
  • Chlorobenzene
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Secondary carboxylic acid amide
  • Lactam
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Alkanolamine
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sodium:potassium:chloride symporter activity
Specific Function:
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name:
SLC12A1
Uniprot ID:
Q13621
Molecular Weight:
121449.13 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 04, 2016 02:45